Pharmacological approach to cardiovascular risk in metabolic syndrome

Journal of Cardiovascular Medicine

Volumn 14, Issue 6, 2013, Pages 403-409

  Bellis, Alessandro ^a   Trimarco, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cardiovascular risk; Insulin resistance; Metabolic syndrome; Oxidative stress

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; METOPROLOL; NEBIVOLOL; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ABDOMINAL FAT; ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; AORTA COARCTATION; BRAIN DAMAGE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HIPPOCAMPUS; HUMAN; HYPERTENSION; IMMUNOREACTIVITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MICROALBUMINURIA; NERVE CELL DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SYSTEMATIC REVIEW (TOPIC); VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; EXERCISE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; RISK FACTORS;

EID: 84879500252     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32835dbd0d     Document Type: Review

References (63)

1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752. (Pubitemid 41532612)
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
3. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
4. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin- convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
5. Poulet R, Gentile MT, Vecchione C, et al. Acute hypertension induces oxidative stress in brain tissues. J Cereb Blood Flow Metab 2006; 26:253-262. (Pubitemid 43151580)
6. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker.NEngl J Med2006; 354:1685-1697.
7. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997; 157:657-667.
8. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006; 24:983-991. (Pubitemid 43772300)
9. Cuocolo A, Storto G, Izzo R, et al. Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril. J Hypertens 1999; 17:1759- 1766.
10. Olefsky J, Farquhar JW, Reaven G. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes 1973; 22:507- 513.
11. Kolterman OG, Insel J, Saekow M, Olefsky JM. Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. J Clin Invest 1980; 65:1272-1284. (Pubitemid 10122368)
12. Lembo G, Napoli R, Capaldo B, et al. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J Clin Invest 1992; 90:24-29.
13. Lembo G, Iaccarino G, Vecchione C, et al. Insulin modulation of vascular reactivity is already impaired in prehypertensive spontaneously hypertensive rats. Hypertension 1995; 26:290-293.
14. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86:3257-3265. (Pubitemid 32674120)
15. Dandona P, Aljada A, Mohanty P, et al. Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care 2003; 26:3310-3314. (Pubitemid 37466892)
16. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
17. Klein J, Fasshauer M, Ito M, et al. Beta(3)-adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes. J Biol Chem 1999; 274:34795- 34802. (Pubitemid 129509523)
18. Morisco C, Condorelli G, Trimarco V, et al. Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res 2005; 96:180-188. (Pubitemid 40209365)
19. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286:1882-1885. (Pubitemid 33010241)
20. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022- 2031. (Pubitemid 38781102)
21. Sowers Jr. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286:H1597-H1602. (Pubitemid 38525443)
22. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133-141.
23. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207. (Pubitemid 46111014)
24. Brixius K, Bundkirchen A, Bolck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001; 133:1330-1338. (Pubitemid 32783494)
25. Weber MA. The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens 2005; 18:169S-176S. (Pubitemid 41803605)
26. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-2236. (Pubitemid 39473160)
27. Mason RP, Kubant R, Jacob RF, et al. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol 2006; 48:862-869. (Pubitemid 44276465)
28. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274:1067-1071.
29. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001; 19:1429-1435. (Pubitemid 32730460)
30. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24:591-596. (Pubitemid 43261924)
31. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of betablockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008; 117:2706-2715; discussion 2715.
32. Fruchart JC, Nierman MC, Stroes ES, et al. New risk factors for atherosclerosis and patient risk assessment. Circulation 2004; 109:III15- III19. (Pubitemid 38786438)
33. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48:937-942. (Pubitemid 29226337)
34. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C: dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49:1939-1945.
35. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86:494-501. (Pubitemid 30165039)
36. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105:1656-1662. (Pubitemid 34298608)
37. Abo A, Pick E, Hall A, et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 1991; 353:668-670. (Pubitemid 21912587)
38. Diekmann D, Abo A, Johnston C, et al. Interaction of Rac with p67phox and regulation of phagocytic NADPH oxidase activity. Science 1994; 265:531-533.
39. Vecchione C, Aretini A, Marino G, et al. Selective Rac-1 inhibition protects from diabetes-induced vascular injury. Circ Res 2006; 98:218-225.
40. Vecchione C, Gentile MT, Aretini A, et al. A novel mechanism of action for statins against diabetes-induced oxidative stress. Diabetologia 2007; 50:874-880. (Pubitemid 46355833)
41. Kirpichnikov D, McFarlane SI, Sowers Jr. Metformin: an update. Ann Intern Med 2002; 137:25-33. (Pubitemid 34705373)
42. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008; 5:157-167.
43. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52:17-30.
44. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-865.
45. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
46. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
47. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289. (Pubitemid 41416583)
48. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 2007; 298:1180-1188. (Pubitemid 47403104)
49. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471. (Pubitemid 46919772)
50. Menendez R, Fernandez SI, Del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994; 27:199-203.
51. Menendez R, Amor AM, Gonzalez RM, et al. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res 1996; 29:253-257. (Pubitemid 26176387)
52. Menendez R, Amor AM, Rodeiro I, et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res 2001; 32:8-12. (Pubitemid 32229906)
53. Man RY, Lynn EG, Cheung F, Tsang PS, O K. Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). Mol Cell Biochem 2002; 233:153-158. (Pubitemid 34752143)
54. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10:1344-1351. (Pubitemid 40022716)
55. Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinasedependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005; 25:2170-2176. (Pubitemid 41416317)
56. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
57. Menotti A, Lanti M, Agabiti-Rosei E, et al. Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies. Nutr Metab Cardiovasc Dis 2005; 15:426-440. (Pubitemid 43986478)
58. Levine JA. Exercise: a walk in the park? Mayo Clin Proc 2007; 82:797-798. (Pubitemid 47015456)
59. Healy GN, Dunstan DW, Salmon J, et al. Objectively measured lightintensity physical activity is independently associated with 2-h plasma glucose. Diabetes Care 2007; 30:1384-1389. (Pubitemid 46871142)
60. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002; 347:1483-1492. (Pubitemid 35257587)
61. Kay SJ, Fiatarone Singh MA. The influence of physical activity on abdominal fat: a systematic review of the literature. Obes Rev 2006; 7:183-200.
62. Church TS, Barlow CE, Earnest CP, et al. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol 2002; 22:1869-1876. (Pubitemid 35315775)
63. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350. (Pubitemid 32378388)